Myelodysplastic Syndrome
Conditions
Keywords
myelodysplastic syndrome, decitabine, spliceosome mutation
Brief summary
In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.
Detailed description
A number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance. Moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in MDS has never been explored yet. The investigators investigated the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes of 1st line decitabine treatment in MDS.
Interventions
GENETICspliceosome
spliceosome mutations
Sponsors
Samsung Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
17 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* de novo MDS patients were included in the study who had received 1st line decitabine treatment and had adequate genomic DNA from pretreated bone marrow samples
Exclusion criteria
* therapy-related MDS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | Two years |
Countries
South Korea
Outcome results
None listed